EMA: scaling for AUC = utopia [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2021-08-03 14:54 (552 d 16:19 ago) – Posting: # 22501
Views: 2,391

Hi kratos,

❝ Just wanted to understand if the EMA would also start accepting scaling for AUC;

❝ There are several locally acting products where the AUC could be more variable than the Cmax parameter.


Correct.

❝ At the moment it appears only the EMA has restricted scaling to Cmax parameter …


Almost correct. Acceptable for MR products’ partial AUCs and Cτ,ss as well.

❝ … while other agencies have extended it to AUC as well.


Which ones? At least, none of the ones applying Average Bioequivalence with Expanding Limits (ABEL). Given, Health Canada accepts ABEL for AUC only.
Reference-scaled Average Bioequivalence (RSABE) – acceptable by the U.S. FDA and China’s CDE for any PK metric – is another cup of tea.

❝ Please, your thoughts on the same.


IMHO, it’s high time to revise the EMA’s GL of 2010. The mills of God grind slowly.
Perhaps the ICH works faster.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
24 visitors (0 registered, 24 guests [including 10 identified bots]).
Forum time: 06:14 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5